Price cap on cancer drugs: A new lifeline?
The recent regulation on trade margin rationalisation (TMR) for 137 non-scheduled anti-cancer drugs came into effect on November 9. Based on the decision of the National Pharmaceutical Pricing Authority (NPPA), trade margins have been capped at 30 per cent. That is, the margin or the markup between the price at which hospitals or distributors buy a certain drug and the price that a patient pays will be capped at a maximum of 30 per cent. The 137 drugs will cover more than 1364 formulations. Calculations and estimates show that the maximum retail prices (MRP) of the capped drugs could come down by 70 to 96 per cent. An annual saving of over Rs 3,500 crore for patients is being projected through this pricing reform.
The Business Standard webinar will examine the fine print of the price cap regulation to explain what it will mean on the ground and what more needs to be done for it to benefit the patients in the true sense.